Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.23) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.05. The company earned $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business's quarterly revenue was up 175.5% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS. View Celldex Therapeutics' Earnings History.

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Celldex Therapeutics.

7 brokers have issued 1 year price objectives for Celldex Therapeutics' stock. Their predictions range from $3.00 to $10.00. On average, they expect Celldex Therapeutics' stock price to reach $6.50 in the next year. View Analyst Ratings for Celldex Therapeutics.

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

• 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
• 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
• 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Celldex Therapeutics saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 7,177,400 shares, a decrease of 42.3% from the September 15th total of 12,438,468 shares. Based on an average trading volume of 1,772,046 shares, the short-interest ratio is currently 4.1 days. Approximately 5.6% of the company's stock are short sold.

Some companies that are related to Celldex Therapeutics include CRISPR THERAPTC (CRSP), ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), ImmunoGen (IMGN), WAVE Life Sciences (WVE), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Celyad SA (CYAD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), PDL BioPharma (PDLI), Agenus (AGEN), Kala Pharmaceuticals (KALA), Adamas Pharmaceuticals (ADMS), Cara Therapeutics (CARA), Arbutus Biopharma Corporation (ABUS), Idera Pharmaceuticals (IDRA) and Codexis (CDXS).

Celldex Therapeutics' management team includes the folowing people:

• Larry Ellberger, Independent Chairman of the Board
• Anthony S. Marucci, President, Chief Executive Officer, Director
• Sam Martin, Chief Financial Officer, Senior Vice President
• Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
• Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
• Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration
• Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
• Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
• Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
• Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.96.